MammoScreen

Therapixel

MammoScreen helps radiologists to identify findings on screening mammograms and assess their level of suspicion. MammoScreen™ uses the MammoScreen Score™ to provide a level-of-suspicion scoring of screenings; confirming certain findings, and pointing out unsure cases.
Product specifications Information source: Vendor
Last updated: Jan. 7, 2021
General
Product name MammoScreen
Company Therapixel
Subspeciality Breast
Modality Mammography
Disease targeted breast cancer
Key-features Lesion detection and characterization, level-of-suspicion score
Suggested use During: perception aid (prompting all abnormalities/results/heatmaps)
Data characteristics
Population Screening mammography
Input Screening 2D FFDM
Input format DICOM
Output Visual report with detected and assessed lesions
Output format Web interface
Technology
Integration Integration via AI marketplace or distribution platform, Stand-alone webbased
Deployment Cloud-based
Trigger for analysis Automatically, right after the image acquisition
Processing time 10 - 60 seconds
Certification
CE
Certified, Class IIa , MDD
FDA
510(k) cleared, Class II
Market presence
On market since 12-2020
Distribution channels Arterys, Softway Medical, others on demand
Countries present (clinical, non-research use)
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing
Pricing model Pay-per-use
Based on Number of analyses
Evidence
Peer reviewed papers on performance

  • Evaluation of Combined Artificial Intelligence and Radiologist Assessment to Interpret Screening Mammograms (read)

  • Improving Breast Cancer Detection Accuracy of Mammography with the Concurrent Use of an Artificial Intelligence Tool (read)

Non-peer reviewed papers on performance

  • Breast screening and artificial intelligence: an independent evaluation of two different software carried out at Valenciennes hospital (read)

Other relevant papers